


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**


1. (currently amended): A composition comprising:  
a thiazole derivative of the formula (I):



wherein

$R^1$  is acyl;

$X$  is a bivalent residue selected from the group consisting of





and


and may be substituted;

$Y$  is a bond, lower alkylene, lower alkenylene or  $-CONH-$ ; and

$Z$  is a group of the formula:



wherein  $R^2$  is a group of the formula:



(wherein  $G$  is a bond,  $-NHCOPH_2-$  or lower alkylene and  $R^4$  is hydrogen,  $-NH_2$  or lower alkyl);

~~A B D E~~


~~— wherein A is a bond, lower alkylene, NH or SO<sub>2</sub>;~~

~~— B is a bond, lower alkylene, CO or O;~~

~~— D is a bond, lower alkylene, NH or CH<sub>2</sub>NH, provided that when B is CO or~~

~~O, D is not a bond; and~~

~~— E is optionally protected amino, N=CH<sub>2</sub>,~~



~~wherein~~

~~— Q is S or NH; and~~

~~— R<sup>3</sup> is hydrogen, lower alkyl, lower alkylthio or~~

~~— NH-R<sup>4</sup> wherein R<sup>4</sup> is hydrogen, NH<sub>2</sub> or~~

~~lower alkyl;~~


or a pharmaceutically acceptable salt thereof,

water, and


an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid.

2. (canceled).

3. (currently amended): The composition of ~~claim 2~~ claim 1, wherein R<sup>2</sup> of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH<sub>2</sub>- or lower alkylene and R<sup>4</sup> is hydrogen or lower alkyl);  
 $\text{CH}_2\text{NH}_2$ ;  $\text{CH}_2\text{ONH}_2$ ;  $\text{CH}_2\text{ON}=\text{CH}_2$ ;



or a pharmaceutically acceptable salt thereof.

4. (previously presented): The composition of claim 1, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

5. (previously presented): The composition of claim 1, wherein the thiazole derivative is N-{4-[2-(4- {[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,  
N-{4-[2-(4- {[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,  
N-{4-[2-(4- {[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,  
N-{4-[2-(4- {[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

or

N-(4-{2-[4-(2- {[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

6. (currently amended): The composition of ~~claim 2~~ claim 1, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

7. (previously presented): The composition of claim 3, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

8. (previously presented): The composition of Claim 1, wherein the additive is glycerin.

9. (previously presented): The composition of Claim 1, wherein the additive is mannitol.

10. (previously presented): The composition of Claim 1, wherein the additive is boric acid or a salt of boric acid.